Tuesday, September 7, 2010

WPI & Cerus Announce Inactivation of XMRV

9/7/10 6:20 PM
Whittemore Peterson Institute and Cerus Announce Inactivation of XMRV…
lood Cells by the INTERCEPT Blood System | EON: Enhanced Online News
Page 1 of 3
http://eon.businesswire.com/news/eon/20100907005755/en
"The INTERCEPT
technology
demonstrates robust
inactivation of these
viruses and holds
promise as a potential
proactive approach to
mitigating the risk of
XMLV/MLV-related
virus transmission via
transfusion."

Whittemore Peterson Institute and Cerus Announce Inactivation of XMRV 
in Platelets
and Red Blood Cells by the INTERCEPT Blood System
- Data Confirming Inactivation of XMRV and MLV-Related Viruses is 
Presented at 1st International XMRV
Workshop -
September 07, 2010 10:03 AM Eastern Daylight Time
RENO, Nev. & CONCORD, Calif.--(EON: Enhanced Online News)--The 
Whittemore Peterson Institute for Neuro-Immune
Disease (WPI) and Cerus Corporation (NASDAQ:CERS) presented data at 
today's NIH-sponsored 1st International
Workshop on XMRV which demonstrates the efficacy of Cerus' INTERCEPT 
Blood System to inactivate XMRV and other
MLV-related viruses in donated blood. Recent scientific studies have 
detected these human retroviruses in up to seven
percent of healthy blood donor samples, indicating approximately 20 
million people in the United States could
unknowingly be carrying the infection. XMRV and MLV-related viruses 
have been linked to prostate cancer and myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS).
"The genetic variability of XMRV and MLV-related viruses will make 
development of
screening assays for the blood supply challenging," said Dr. Judy 
Mikovits, director of
research at WPI and lead author of the study. "The INTERCEPT 
technology demonstrates
robust inactivation of these viruses and holds promise as a potential 
proactive approach
to mitigating the risk of XMLV/MLV-related virus transmission via 
transfusion."
Co-author Dr. Lily Lin, vice president of global scientific affairs 
for Cerus, added, "The INTERCEPT system inactivates pathogens by crosslinking their DNA or RNA, which blocks their ability to replicate and prevents transmission of the infection. 
This mechanism of
action is designed to provide prospective protection against emerging 
threats like XMRV
and its genetic variants."
In a paper published online on August 23, 2010 in the journal 
Proceedings of the
National Academy of Sciences (PNAS), scientists from the National 
Institutes of Health
and U.S. Food and Drug Agency detected the presence of a genetically 
diverse group of
MLV-related viruses in 86 percent of CFS patient samples and in 6.8 
percent of samples
from healthy blood donors, leading to new concerns about the 
possibility of transfusion transmission. The PNAS study
results are consistent with data from a 2009 study published in 
Science, which detected XMRV in 67 percent of CFS
patients and 3.7 percent of healthy controls.
In the study conducted by WPI and Cerus, red blood cell and platelet 
components were contaminated with a natural
isolate of XMRV and MLV-related viruses from an ME/CFS patient. 
INTERCEPT-treated and control samples were
evaluated in a validated virus culture test, which allows sensitive 
detection of viral particles that are capable of
reproducing. No viable virus was detected following treatment, 
indicating the INTERCEPT Blood System is capable of
inactivating high levels (>4 logs) of the virus.
The INTERCEPT systems for platelets and plasma are used by over 60 
blood centers in Europe, Russia and the Middle
East. The INTERCEPT red cell system is in clinical development. The 
INTERCEPT Blood System is not yet approved for use
in the United States.
ABOUT THE WHITTEMORE PETERSON INSTITUTE
The Whittemore Peterson Institute for Neuro Immune Disease exists to 
bring discovery, knowledge, and effective
treatments to patients with illnesses that are caused by acquired 
dysregulation of both the immune system and the
nervous system, often resulting in lifelong disease and disability. 
The Whittemore Peterson Institute is the first institute in
the world dedicated to neuro-immune diseases, integrating patient 
treatment, basic and clinical research and medical
education.
ABOUT CERUS
9/7/10 6:20 PM
Whittemore Peterson Institute and Cerus Announce Inactivation of XMRV…
lood Cells by the INTERCEPT Blood System | EON: Enhanced Online News
Page 2 of 3
http://eon.businesswire.com/news/eon/20100907005755/en
Cerus Corporation is a biomedical products company focused on 
commercializing the INTERCEPT Blood System to
enhance blood safety. The INTERCEPT system is designed to reduce the 
risk of transfusion-transmitted diseases by
inactivating a broad range of pathogens such as viruses, bacteria and 
parasites that may be present in donated blood.
The nucleic acid targeting mechanism of action allows INTERCEPT 
treatment to inactivate both established transfusion
threats, such as hepatitis, HIV, West Nile virus and bacteria, as well 
as emerging pathogens such as influenza, malaria
and dengue. Cerus currently markets and sells the INTERCEPT Blood 
System for both platelets and plasma in Europe,
Russia, the Middle East and selected countries in other regions around 
the world. The INTERCEPT red blood cell system
is in clinical development. Visit http://www.cerus.com  for more 
information.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus 
Corporation.
References
1. Lo SC, et al. (2010) Detection of MLV-related virus gene sequences 
in blood of patients with chronic fatigue syndrome
and healthy blood donors. Proceedings of the National Academy of 
Sciences, published online before print August 23,
2010.
http://www.pnas.org/content/early/2010/08/16/1006901107.full.pdf+html
2. Lombardi VC, et al. (2009) Detection of an infectious retrovirus, 
XMRV, in blood cells of patients with chronic fatigue
syndrome. Science 326:585–589.
http://www.sciencemag.org/cgi/content/abstract/1179052
3. Mikovits J, et al. (2010) Inactivation of XMRV and MLV-related 
viruses in platelet and RBC components prepared with
the INTERCEPT Blood System. Presented at the 1st International 
Workshop on XMRV, September 7-8, 2010 (Bethesda,
MD).
http://www.interceptbloodsystem.com/recent_publications.html
Contacts
R&R Partners for
Whittemore Peterson Institute
Amy Riley, 775-287-7930
amy.riley@rrpartners.com
or
Cerus Corporation
Lainie Corten, 925-288-6319
Director, Global Communications & Marketing
Permalink: http://eon.businesswire.com/news/eon/20100907005755/en/Cerus-Corporation/Whittemore-Peterson-Institute/blood-safety
View All Releases from This Organization
Multimedia Gallery
Logo
Logo
Release Tags
Cerus Corporation  Whittemore Peterson Institute  blood safety  
intercept blood system pathogen inactivation
News by Industry
Biotechnology (Health & Medicine)
Health & Medicine
Infectious Diseases
News by Subject
Conference
News by Geography
California
Nevada
North America
United States
Categories
9/7/10 6:20 PM
Whittemore Peterson Institute and Cerus Announce Inactivation of XMRV…
lood Cells by the INTERCEPT Blood System | EON: Enhanced Online News
Page 3 of 3
http://eon.businesswire.com/news/eon/20100907005755/en

No comments: